Polymerase III-based expression of therapeutic RNAS

Details Polymerase III-based expression of therapeutic RNAS Polymerase III-based expression of therapeutic RNAS

2005-02-08

2005-02-08

Lacourciere, Karen A. (Department: 1635)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S006120, C435S325000, C536S024500, C536S024300, C536S024310, C536S024330

Reexamination Certificate

active

06852535

ABSTRACT:
A transcribed non-naturally occurring RNA molecule comprising a desired RNA molecule, wherein the 3′ region of the RNA is able to base-pair with at least 8 bases at the 5′ terminus of the same RNA molecule.

REFERENCES:
patent: 5208149 (1993-05-01), Inouye
patent: 5324643 (1994-06-01), Greatbatch et al.
patent: 5624803 (1997-04-01), Noonberg et al.
patent: 5902880 (1999-05-01), Thompson
patent: 6146886 (2000-11-01), Thompson
patent: WO 8911539 (1989-11-01), None
patent: WO 9013641 (1990-11-01), None
patent: WO 9207065 (1992-04-01), None
patent: WO 9311253 (1993-06-01), None
patent: WO 9323057 (1993-11-01), None
patent: WO 9323569 (1993-11-01), None
patent: WO 9402495 (1994-02-01), None
patent: WO 9416736 (1994-08-01), None
patent: WO 9424983 (1994-11-01), None
patent: WO 9429452 (1994-12-01), None
Verma et al, Gene therapy—promises, problems and prospects, Sep. 1997, Nature, vol. 389, pp. 239-242.*
W. French Anderson, Human Gene Therapy, Apr. 1998, Nature, vol. 392, pp. 25-30.*
Orkin et al, Report and recommendations of the panel to assess the NIH investment in research on gene therapy, Dec. 1995, NIH, pp. 1-31.*
Ellington et al. In vitro selection of RNA molecules that bind specific ligands. Nature. vol. 346, Aug. 30, 1990, pp. 818-882.*
Cameron and Jennings, “Specific Gene Expression by Engineered Ribozymes in Monkey Cells,” Proc. Natl. Acad. Sci. USA 86:9139-9143 (1989).
Cushman et al., 1996, “Ribozyme Inhibition of VEGF-Mediated Endothelial Cell Proliferation in Cell Culture and VEGF-Induced Angiogenesis in a Rat Corneal Model” Abstract in IBC USA Conferences—Angiogenesis Inhibitors.
Desjardins et al., “Pharmacokinetics of a Synthetic, Chemically Modified Hammerhead Ribozyme Against the Rat Cytochrome P-450 3A2 Mrna After Single Intravenous Injections,” J. Pharmacology and Experimental Therapeutics 27(8):1419-1427 (1996).
Efrat et al., “Ribozyme-mediated attenuation of pancreatic β-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion,” Proc. Natl. Acad. Sci. USA 91:2051-2055 (1994).
Flory et al., “Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint,” Proc. Natl. Acad. Sci. USA 93:754-758 (1996).
Larsson et al., “Reduced β2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme,” Nucleic Acids Research 22(12):2242-2248 (1994).
Lieber and Kay, “Adenovirus-Mediated Expression of Ribozymes in Mice,” Journal of Virology 70(5):3153-3158 (1996).
Lyngstadaas et al., “A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo,” EMBO J. 14:5224-5229 (1995).
Malone et al., “Cationic liposome-mediated RNA transfection”, Proc. Nat. Acad. Sci. USA 86:6077 (1989).
RPI Press Release, Aug. 29, 2001, http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=742975&TICK=RZYM&STORY=/www/story/08-29-2001/0001562763&EDATE=Aug+29,+2001.
RPI Press Release, Jun. 20, 2001, http://www.prnewswire.com/cgi-bin/micro_stories.pl?ACCT=742975&TICK=RZYM&STORY=/www/story/06-20-2001/0001517763&EDATE=Jun+20,+2001.
RPI Press Release, Oct. 8, 2001, http://www.prnewswire.com/cgi-bin/micro_stories.p1?ACCT=742975&TICK=RZYM&STORY=/www/story/10-08-2001/0001586793&EDATE=Oct+8,+2001.
Sambrook et al. (Molecular Cloning, A Laboratory Manual, 2nd ed., 1989, sections 16.30-.32).
Seachrist, Bioworld Today, Jan. 15, 1997, at http:www.bioworld.com/bw/static.htm?path=br/data/bt01151997/bt01151997e.html.
Sioud, “Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-α production by peritoneal cells in vitro and in vivo,” Eur. J. Immunol. 26:1026-1031 (1996).
Uhlmann and Peyman, “Antisense Oligonucleotides: A New Therapeutic Principle,” Chemical Reviews 90:544-584 (1990).
Yamamoto et al., “Abrogation of Lung Metastasis of Human Fibrosarcoma Cells by Ribozyme-Mediated Suppression of Integrin α6 Subunit Expression,” Int. J. Cancer 65:519-524 (1996).
Adeniyi-Jones et al., “Generation of long read- through transcripts in vivo and in vitro by deletion 3′ termination and processing sequences in the human tRNAimet gene,” Nucleic Acids Research 12:1101-1115 (1984).
Ashom et al., “Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors,” Proc. Natl. Acad. Sci. USA 87:8889-8893 (1990).
Ballantyne et al., “Nucleotide sequence of the cDNA for murine intercellular adhesion molecule-1 (ICAM-1),” Nucleic Acids Research 17:5853 (1989).
Bahner et al., “Comparison of trans-Dominant Inhibitory Mutant Human Immunodeficiency Virus Type 1 Genes Expressed by Retroviral Vectors in Human T-Lymphocytess,” J. Virology 67:3199-3207 (1993).
Baltimore, “Intracellular Immunization,” Nature 335:395-396 (1988).
Barinaga, “Ribozymes: Killing the Messenger,” Science 262:1512-1514 (1993).
Berkner, “Development of Adenovirus Vectors for the Expression of Heterologous Genes,” BioTechniques 6:616-629 (1988).
Bredow et al., “Sequence and factor requirements for faithful in vitro transcription of human 7SL DNA,” Gene 86:217-225 (1990).
Carter, Curr. Opin. Genet. Dev. 3:74 (1992).
Cech, “Ribozymes and Their Medical Implications,” JAMA 260:3030-3034 (1988).
Chomcyzynski and Sacchi, “Single Step Method of RNA Isolation by Acid Guanidinum Thiocyanate-Phenol-Chloroform Extraction,” Analytical Biochem. 162:156-159 (1987).
Cotten and Birnstiel, “Ribozyme Mediated Destruction of RNA in vivo,” EBMO J 8:3861-3865 (1989).
Cotten, “The in vivo application of ribozymes,” TIBTECH 8:174-178 (1990).
Edgington, “Ribozymes: Stop Making Sense,” Biotechnology 10:256-262 (1992).
Eguchi et al., “Antisense RNA,” Annu. Rev. Biochem. 60:631-652 (1991).
Fowlkes and Shenk, “Transcriptional Control Regions of the Adenovirus VAI RNA Gene,” Cell 22:405-413 (1980).
Geiduschek and Tocchini-Valentini, “Transcription by RNA Polymerase III,” Ann. Rev. Biochem. 57:873-914 (1988).
Gupta and Reddy, “Compilation of small RNA sequences,” Acids Research 19 (Supplement):2073-2075 (1991).
Hall et al., “Transcription Initiation of Eucaryotic Transfer RNA Genes,” Cell 29:3-5 (1982).
Howe and Shu, “Epstein-Barr Virus Small RNA (EBER) Genes: Unique Transcription Units That Combine RNA Polymerase II and III Promoter Elements,” Cell 57:825-834 (1989).
Kickhoefer et al., “Vault Ribonucleoprotein Particles from Rat and Bullfrog Contain a Related Small RNA That Is Transcribed by RNA Polymerase III,” J. Biol. Chem. 268:7868-7873 (1993).
Kita et al., “Sequence and expression of rat ICAM-1,” Biochem. Biophys. Acta 1131:108-110 (1992).
Lee et al., “Transcription of Xenopus Selenocysteine tRNASer (Formerly Designated Opal Suppressor Phosphoserine tRNA) Gene Is Directed by Mutible 5′-Extragenic Regulatory Elements,” J. Biol. Chem. 264:9696-9702 (1989).
Lee et al., “Overexpression of RRE-Derived Sequences Inhibits HIV-1 Replication in CEM Cells,” The New Biologist 4:66-74 (1992).
Lieber and Strauss, Selection of Efficient Cleavage Sites in Target RNAs by Using a Ribozyme Expression Library, Mol. Cellular Biol. 15:540-551 (1995).
Malim et al., “Functional Comparison of the Rev Trans-activators Encoded by Different Primate Immunodeficiency Virus Species” Proc. Natl. Acad. Sci. USA 86:8222-8226 (1989).
Mattaj et al., “Changing the RNA Polymerase Specificity of U snRNA Gene Promoters,” Cell 55:435-442 (1988).
Nielsen et al., “Transcription of Human 5S rRNA Ge

Affiliated with

Also associated with

Rating

Polymerase III-based expression of therapeutic RNAS does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymerase III-based expression of therapeutic RNAS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymerase III-based expression of therapeutic RNAS will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3492799